NCT Number: NCT06395519
Phase: PHASE1
Trial Summary: This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor acti – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): 858 Therapeutics, Inc.
Acronym: ERADIC8
High Risk Prostate Cancer
Clinical trials for patients diagnosed with high risk prostate cancer: Patients with a diagnosis that includes a PSA more than 20, or Gleason 8-10, or tumor has spread outside the prostate. (Stage 2-3)
A Randomised Controlled Trial to Evaluate the Impact of Complement Theory’s Live 1:1 Exercise Coaching and Personalised Digital Application on Cancer Survivors’ Cost of Care
NCT Number: NCT06397651
Phase: NA
Trial Summary: A Decentralized, Double-blinded, Randomized, 18 month, Parallel-group, Superiority Study to evaluate the impact of Complement Theory’s Live 1:1 Exercise Coaching and Personalized Digital Application o – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Complement Theory Inc.
Acronym:
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT Number: NCT06235151
Phase: PHASE3
Trial Summary: This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very h – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Curium US LLC
Acronym: Solar-Stage
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT Number: NCT06257264
Phase: PHASE1
Trial Summary: This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and pre – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): BeiGene
Acronym:
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
NCT Number: NCT06305598
Phase: PHASE1
Trial Summary: This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration resistant prostate can – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Roswell Park Cancer Institute
Acronym:
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
NCT Number: NCT06347705
Phase: PHASE2
Trial Summary: The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system t – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): MidLantic Urology
Acronym:
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer
NCT Number: NCT06369610
Phase: PHASE2
Trial Summary: This phase II trial tests how well risk based de-escalated hormone therapy (i.e., fewer treatments) with radiation works in treating patients with prostate cancer. Androgen deprivation therapy (ADT), – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Mayo Clinic
Acronym:
GU-01: Glycyrrhizin in Prostate Cancer
NCT Number: NCT06378346
Phase: PHASE2
Trial Summary: This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy) – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Illinois at Chicago
Acronym: GU-01
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
NCT Number: NCT06212583
Phase: PHASE2
Trial Summary: The purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of California, Davis
Acronym: KNIGHTS
Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer
NCT Number: NCT06228053
Phase: PHASE2
Trial Summary: The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed abiraterone. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Syntrix Biosystems, Inc.
Acronym: SYNERGY-201
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
NCT Number: NCT06235099
Phase: PHASE3
Trial Summary: This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation ther – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Curium US LLC
Acronym: Solar-Recur
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
NCT Number: NCT06067269
Phase: PHASE2
Trial Summary: This phase II trial evaluates apalutamide in combination with image-guided stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate cancer. Prostate cancer usually needs – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Jonsson Comprehensive Cancer Center
Acronym: HEATWAVE
Geriatric Assessment and Promotores (GAP) Pilot Feasibility Study
NCT Number: NCT06125145
Phase: PHASE2
Trial Summary: The goal of this clinical trial is to test a new way to help older adults who have had cancer. The researchers want to see if a program that assesses participants health and aging is achievable and m – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of California, Davis
Acronym: GAP
Pilot Study for Black Men With Prostate Cancer: Optimization Of Mental and Heart Health, the BOOM-Heart Study
NCT Number: NCT05099679
Phase: NA
Trial Summary: Pilot study to determine the feasibility of providing psychosocial and cardiac rehabilitation services to address socioeconomic health disparities and improve wellbeing for black m – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Stanford University
Acronym:
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
NCT Number: NCT05155046
Phase: Phase 2
Trial Summary: Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET s – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:
Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
NCT Number: NCT05415696
Phase: NA
Trial Summary: The purpose of this study is to learn if the prostatic artery embolization procedure can reduce urinary tract symptoms in patients with enlarged prostates and prostate cancer. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Stanford University
Acronym:
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
NCT Number: NCT05593497
Phase: PHASE2
Trial Summary: The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help i – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): VA Office of Research and Development
Acronym: SNARE
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
NCT Number: NCT06389786
Phase: NA
Trial Summary: This clinical trial evaluates the use of an imaging scan (18F-rhPSMA-7.3 positron emission tomography [PET]/magnetic resonance imaging [MRI]) for identifying patients who are at risk of having the – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Mayo Clinic
Acronym:
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
NCT Number: NCT04134260
Phase: Phase 3
Trial Summary: This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therap – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): NRG Oncology
Acronym:
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT Number: NCT04513717
Phase: Phase 3
Trial Summary: This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): NRG Oncology
Acronym:
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
NCT Number: NCT06451497
Phase: PHASE1
Trial Summary: This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Pembrolizumab in patients with advanced solid tumors who have exhausted all stand – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Zumutor Biologics Inc.
Acronym:
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
NCT Number: NCT06257693
Phase: PHASE1
Trial Summary: The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Alessa Therapeutics Inc.
Acronym:
Relationship bw Image-deriv Features of Intraoperative ICG Visualiz of NVBs During RARP & Functional Outcome
NCT Number: NCT06446648
Phase: EARLY_PHASE1
Trial Summary: This is a pilot, 3 phases open-label feasibility study with the 3rd phase consisting of randomized 2-arm intervention trial, to assess the systematic use of indocyanine green (ICG) in subjects with pr – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of California, Irvine
Acronym:
Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer
NCT Number: NCT04887935
Phase: PHASE1
Trial Summary: This is a study of the tolerability and safety of neoadjuvant dapagliflozin for patients with high-risk or very high risk prostatic adenocarcinoma prior to radical prostatectomy. The primary hypothesi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Washington University School of Medicine
Acronym:
CV CARE: CardioVascular Care in PC Patients
NCT Number: NCT06202820
Phase: NA
Trial Summary: This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with th – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym:
A Trial for a Preliminary Estimate of the Effectiveness of a Novel Theoretical Framework
NCT Number: NCT06461416
Phase: NA
Trial Summary: Aim 1: To determine the preliminary effect sizes of al ActiveHeal EST (Engage-Sustain-Triumph) Program on occupational resilience. – clinicaltrials.gov for more information and locations
* Aim 2: To determine the preliminary effect sizes of ActiveHeal ES – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Arkansas
Acronym:
PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer
NCT Number: NCT06369246
Phase: PHASE2
Trial Summary: To look at the safety and effectiveness of stereotactic body radiation therapy (SBRT) in treating advanced or high-risk prostate cancer. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): M.D. Anderson Cancer Center
Acronym:
Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
NCT Number: NCT06343077
Phase: PHASE2
Trial Summary: This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Chicago
Acronym:
MRI Guided Prostate Biopsy
NCT Number: NCT06302595
Phase: NA
Trial Summary: This study aims to assess the feasibility of magnetic resonance (MR) guided prostate biopsy using a needle holder frame. This frame is used to help position the needle used for the biopsy. The feasibi – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Brigham and Women’s Hospital
Acronym:
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
NCT Number: NCT06014255
Phase: PHASE2
Trial Summary: This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acronym: HEAT
PSMA PET Response Guided SabR in High Risk Pca
NCT Number: NCT06044857
Phase: PHASE1
Trial Summary: Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Il – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): University of Texas Southwestern Medical Center
Acronym:
The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
NCT Number: NCT06064149
Phase: NA
Trial Summary: The overarching goal of this trial is to develop mechanisms to improve cardiovascular care among such prostate cancer patients receiving ADT by increasing patient awareness of individualized cardiovas – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Vivek Narayan
Acronym:
Behavioral Exercise Training to Reduce Cardiovascular Disease Risk
NCT Number: NCT06237179
Phase: PHASE1|PHASE2
Trial Summary: To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak & 6-minute walk distance [6MWD]) among prostate cancer (PC) patients – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Virginia Commonwealth University
Acronym: EXTRA-PC
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT Number: NCT05000294
Phase: Phase 1| Phase 2
Trial Summary: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective tr – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): University of Florida
Acronym:
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
NCT Number: NCT05056077
Phase:
Trial Summary: This clinical trial studies the effect of four different intervention components “tools” on body weight, nutrition, and physical activity in cancer survivors. Studies indicate that people with a histo – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): University of California, San Francisco
Acronym: TTBF
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
NCT Number: NCT05530655
Phase: Early Phase I
Trial Summary: This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): University of Rochester
Acronym:
Rectal Spacer for Prostate Cancer Radiation Image Guidance
NCT Number: NCT05650021
Phase:
Trial Summary: The purpose of the study is to determine if a radiopaque hydrogel rectal spacer, SpaceOAR Vue®, can be used in place of fiducial markers when aligning patients for radiotherapy. The investigator hypo – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Milton S. Hershey Medical Center
Acronym:
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
NCT Number: NCT05765500
Phase:
Trial Summary: This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. T – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym:
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
NCT Number: NCT04396808
Phase: Not Applicable
Trial Summary: This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC cl – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Michigan Rogel Cancer Center
Acronym:
Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study
NCT Number: NCT04870515
Phase: Not Applicable
Trial Summary: This clinical trial studies the effects of a diet and physical activity intervention on blood measures of lipids and insulin resistance in patients with prostate cancer undergoing – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fred Hutchinson Cancer Center
Acronym:
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
NCT Number: NCT04943536
Phase: Phase 1
Trial Summary: This study will be undertaken to evaluate the feasibility of replacing systemic Androgen Deprivation Therapy (ADT) with targeted local delivery of an anti-androgen agent alone in p – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Alessa Therapeutics Inc.
Acronym: BiolenRT
PSMA-PET to Guide Prostatectomy
NCT Number: NCT05381103
Phase: Phase 2|Phase 3
Trial Summary: In this study, 288 patients will be randomized 1:1 to either having only the standard of care MRI prior to surgery versus having the standard of care MRI and the PSMA PET scan. PET – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Five Eleven Pharma, Inc.
Acronym:
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations
NCT Number: NCT05498272
Phase: Phase 2
Trial Summary: Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Rana McKay, MD
Acronym: NePtune
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
NCT Number: NCT05628363
Phase: Not Applicable
Trial Summary: This trial is a prospective clinical trial designed to demonstrate the safety and feasibility of whole-pelvis adaptive prostate stereotactic body radiation therapy (SBRT) with a tu – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Washington University School of Medicine
Acronym:
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT Number: NCT05794906
Phase: Phase 3
Trial Summary: Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Bayer
Acronym: ARASTEP
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
NCT Number: NCT04989946
Phase: Phase 1|Phase 2
Trial Summary: The current protocol will examine the use of a plasmid DNA vaccine encoding AR, alone or with nivolumab, to induce and/or augment therapeutic T-cells following androgen deprivation – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Wisconsin, Madison
Acronym:
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT Number: NCT04402151
Phase: Phase 2
Trial Summary: This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym: PSMA SBRT-SIB
RESIST-ADT (Androgen Deprivation Therapy)
NCT Number: NCT04485767
Phase: Not Applicable
Trial Summary: The overall goal of this study is to determine if implementing structured exercises prevent decline in muscle mass, muscle strength and physical function in men with prostate cance – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym:
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
NCT Number: NCT04812366
Phase: Phase 2
Trial Summary: The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of British Columbia
Acronym: GUNS
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
NCT Number: NCT05869682
Phase: PHASE2
Trial Summary: This phase II trial tests how well bright white light (BWL) therapy works in reducing cancer-related fatigue and depression in patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant pa – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): City of Hope Medical Center
Acronym:
The Genomic Medicine at VA Study
NCT Number: NCT04331535
Phase: Not Applicable
Trial Summary: This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Boston VA Research Institute, Inc.
Acronym: GenoVA
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT Number: NCT04585750
Phase: Phase 1|Phase 2
Trial Summary: This study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 alone and in combination with pembrolizumab in participants with advanced solid tumors containing a TP5 – clinicaltrials.gov for more information and locations and locations
Clinicaltrials.gov
Trial Sponsor(s): PMV Pharmaceuticals, Inc
Acronym:
Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer
NCT Number: NCT04346225
Phase: Phase 2
Trial Summary: This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging as a diagnostic and response monitoring tool in patients with advanced prostate cancer. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Rahul Aggarwal
Acronym:
The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.
NCT Number: NCT05010200
Phase: Phase 1
Trial Summary: This proof of concept study is designed to test the safety and tolerability of PGV001-based personalized multi-peptide vaccines in combination with CDX-301 in subjects with a histo – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Ashutosh Kumar Tewari
Acronym: PGV-Prostate
Video Education With Result Dependent dIsclosure
NCT Number: NCT05225428
Phase: Not Applicable
Trial Summary: The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym: VERDI
Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer
NCT Number: NCT05471414
Phase: Not Applicable
Trial Summary: The study is comparing the effect on weight of providing home-delivered whole-food, plant-based meals versus standard, general nutritional counseling to men with prostate cancer on androgen-deprivatio – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym: WFPBD
African Cancer Genome: GMD
NCT Number: NCT05754658
Phase:
Trial Summary: he goal of this study is to develop a comprehensive characterization of genetic and molecular drivers of breast and prostate cancer in individuals of – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fox Chase Cancer Center
Acronym:
Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
NCT Number: NCT05045066
Phase: Early Phase 1
Trial Summary: This early phase I is to find out how common vitamin D deficiency is among African American patients with a history of prostate cancer that has not spread to other parts of the bod – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Mayo Clinic
Acronym:
Prostate Resection After Microwave Ablation (PRAMA)
NCT Number: NCT06128525
Phase: NA
Trial Summary: This phase I trial tests the safety of magnetic resonance imaging (MRI)/ ultrasound (US) fusion guided transperineal targeted microwave ablation (TMA) before a radical prostatectomy (RP) and how well – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Southern California
Acronym:
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
NCT Number: NCT04777071
Phase: Phase 2
Trial Summary: This trial studies how well 68Ga-PSMA-11 PET/CT scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET/CT may find and diagnose prosta – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Washington
Acronym:
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
NCT Number: NCT04768868
Phase: Phase 1
Trial Summary: A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Impact Therapeutics, Inc.
Acronym: WEE1
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
NCT Number: NCT04586270
Phase: PHASE1
Trial Summary: The purpose of this study is to see if TAS0612 is safe in participants with advanced or metastatic solid tumor cancer. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Taiho Oncology, Inc.
Acronym:
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT Number: NCT05806515
Phase: PHASE2
Trial Summary: This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): SWOG Cancer Research Network
Acronym:
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT Number: NCT05946213
Phase: PHASE3
Trial Summary: This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): NRG Oncology
Acronym:
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
NCT Number: NCT06085664
Phase: PHASE1|PHASE2
Trial Summary: To learn about the safety and effects of a drug called REGN5678 when it is given to patients with high-risk prostate cancer. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): M.D. Anderson Cancer Center
Acronym:
A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer
NCT Number: NCT06218667
Phase: PHASE1|PHASE2
Trial Summary: The researchers are doing this study to find out whether copanlisib in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment t – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Memorial Sloan Kettering Cancer Center
Acronym:
High-Dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
NCT Number: NCT05838716
Phase: PHASE3
Trial Summary: This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation t – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Rochester NCORP Research Base
Acronym:
Behavioral Exercise TRaining for Men Undergoing Androgen Depr Therapy for Prostate Ca
NCT Number: NCT06250751
Phase: NA
Trial Summary: To refine a remote behavioral exercise training intervention for testing in a larger randomized trial. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Virginia Commonwealth University
Acronym: BETR-PC
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
NCT Number: NCT06173362
Phase: PHASE2
Trial Summary: This phase II trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Mamta Parikh
Acronym:
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
NCT Number: NCT05960578
Phase: PHASE2
Trial Summary: This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (T – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Washington
Acronym:
Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients With Prostate Cancer
NCT Number: NCT06016504
Phase: NA
Trial Summary: This clinical trial aims to design and validate an adaptive virtual consultation tool (AVCT) for men with prostate cancer (PC). An AVCT utilizes health literacy assessments in combination with learnin – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
Online Dietary and Resistance Training to Improve Physical Function in Older Cancer Survivors, E-PROOF Trial
NCT Number: NCT06016725
Phase: NA
Trial Summary: This phase I trial tests the feasibility, acceptability, and preliminary effectiveness of online dietary and resistance training to improve physical function in older (greater than or equal to 65-year – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym: E-PROOF
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
NCT Number: NCT06018311
Phase: NA
Trial Summary: The purpose of this study is to determine the feasibility and effects of an adapted Exercising Together, a partnered resistance training program, on the physical and mental health of prostate cancer s – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial
NCT Number: NCT06037863
Phase: PHASE2
Trial Summary: This clinical trial evaluates the effects of an empty bladder versus (vs.) a full bladder prior to undergoing a computed tomography (CT) simulation for radiation therapy in patients with prostate canc – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
A Study of Mental Health Care in People With Cancer
NCT Number: NCT06037954
Phase: NA
Trial Summary: The purpose of this study is to look at mental health services for adults with depressed mood who were diagnosed with cancer at the age of 65 or older. This study will compare the usual approach for c – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
IS-002 in Prostate Cancer
NCT Number: NCT05946603
Phase: PHASE2
Trial Summary: Phase 2 randomized controlled multi-center study of IS-002, in conjunction with near-infrared (NIR) fluorescence imaging, for identification of prostate cancer during robotic-assisted radical prostate – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT Number: NCT05969860
Phase: PHASE2
Trial Summary: This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph n – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
A Study to Investigate the Biological Effects of AZD5305, Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
NCT Number: NCT05938270
Phase: PHASE1
Trial Summary: A Study to Investigate the Biological Effects of AZD5305 Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN) – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym: ASCERTAIN
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
NCT Number: NCT03127631
Phase: NA
Trial Summary: RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifesty – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym: RADICALPC
Understanding of Genetics by Men at Risk for Prostate Cancer
NCT Number: NCT04550845
Phase: NA
Trial Summary: With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions. This study is designed to investigate the understand – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer
NCT Number: NCT05754580
Phase: NA
Trial Summary: The objective of this phase I/II trial is to prospectively evaluate the toxicity and therapeutic efficacy of Stereostatic Body Radiation Therapy (SBRT) to prostate and pelvic lymph nodes in combinatio – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors
NCT Number: NCT03971591
Phase: Not Applicable
Trial Summary: This study will examine the efficacy of Men Moving Forward (MMF), a four-month community-based lifestyle intervention designed for AA PC survivors. MMF is rooted in the evidence-ba – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym: MMF
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
NCT Number: NCT00969111
Phase: Not Applicable
Trial Summary: The purpose of this study is to see what effects, good and/or bad, proton radiation, and/or conventional radiation and hormonal therapy (if applicable), has on prostate cancer that – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
NCT Number: NCT04167969
Phase: Phase 1
Trial Summary: The purpose of this study is to see whether using the 64Cu-NOTA-PSMA-PEG-Cy5.5-C’ dot tracer is a safe way to identify tumor cells before and during surgery for prostate cancer. Th – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
NCT Number: NCT03824652
Phase: Phase 2
Trial Summary: This is a randomized control trial testing the effect of walnut supplementation on prostate cancer progression in 50 men with biopsy confirmed prostate cancer and planning to under – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT Number: NCT02960022
Phase: PHASE2
Trial Summary: The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
NCT Number: NCT03821246
Phase: Phase 2
Trial Summary: This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prost – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
NCT Number: NCT04030559
Phase: Phase 2
Trial Summary: This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
NCT Number: NCT04194554
Phase: Phase 1|Phase 2
Trial Summary: The purpose of this study is to establish the maximum tolerable dose of niraparib when combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and pr – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym: ASCLEPIuS
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
NCT Number: NCT02949284
Phase: Phase 2
Trial Summary: This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and predniso – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
NCT Number: NCT06101290
Phase: NA
Trial Summary: This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary o- clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym: LAYOVER
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
NCT Number: NCT03861676
Phase: EARLY_PHASE1
Trial Summary: The Principal Investigator’s (PI) working hypothesis is that the PI can utilize the high predictive value of 18F-DCFPyl PSMA to identify clinically significant tumors in patients who will undergo brac- clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
Low-Intensity Shockwave Therapy to Treat Erectile Dysfunction and Preserve Erectile Function After Prostate Cancer Surgery
NCT Number: NCT05877144
Phase: NA
Trial Summary: This phase I clinical trial studies how well low intensity shockwave therapy (LiSWT) improves erectile function in patients who have had nerve-sparing radical prostatectomy (NS-RP), a type of surgery – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
NCT Number: NCT05899361
Phase: NA
Trial Summary: This research study is a pilot clinical trial, which hypothesizes that the combination of electromagnetic tracking in conjunction with laparoscope imaging and ultrasound probe imaging will aid in redu- clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
NCT Number: NCT06054867
Phase: NA
Trial Summary: The goal of this clinical trial is to evaluate the safety of the AQUABEAM Robotic System in treating patients with localized prostate cancer. Participants will go through baseline and follow up assess- clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT Number: NCT06056830
Phase: PHASE3
Trial Summary: The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.- clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym: CLARIFY
Two Fraction Prostate SBRT With DIL SIB
NCT Number: NCT05864196
Phase: PHASE1
Trial Summary: Phase I/Ib, single arm trial of Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with an MRI directed, dominant intraprostatic lesion (DIL), simultaneous integrated boost (SIB) based on genomic – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): NYU Langone Health
Acronym:
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
NCT Number: NCT05915442
Phase: PHASE2
Trial Summary: This study will evaluate the safety and effectiveness of a combination of study drugs including zimberelimab, etrumadenant, and quemliclustat in combination with metastasis-directed irradiation in men – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Catherine Spina
Acronym: SBRT-AMICO
Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
NCT Number: NCT05828082
Phase: PHASE2
Trial Summary: This phase II trial tests how well M1774 works in treating patients with prostate cancer that does not respond to treatment (refractory) and that has a mutation in the gene responsible for making the – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:
Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer
NCT Number: NCT05851365
Phase:
Trial Summary: This is a single site, prospective pilot study to determine the feasibility and safety of the administration of HP 13C bicarbonate in 10 patients with prostate cancer to determine potential hydrogen ( – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): Robert Flavell, MD, PhD
Acronym:
Collection of Blood From Patients With Cancer
NCT Number: NCT00034216
Phase:
Trial Summary: This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and ol – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
NCT Number: NCT00451022
Phase:
Trial Summary: This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to int – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
NCT Number: NCT02594202
Phase:
Trial Summary: Background:
Prostate cancer is the most common noncutaneous cancer among men in the U.S. Researchers want to study blood, tissue, and fluid samples of people with prostate cancer. This will help them – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:
Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
NCT Number: NCT03354416
Phase:
Trial Summary: Background:
Prostate cancer is one of the most common cancers for men in the U.S. There are some new ways to take pictures of the cancer. There are also new ways to use image-guided biopsy and therap – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:
Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.
NCT Number: NCT04839991
Phase:
Trial Summary: FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety and tolerability to de – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): Crescendo Biologics Ltd.
Acronym: POTENTIA
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
NCT Number: NCT05467176
Phase:
Trial Summary: This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): Myovant Sciences GmbH
Acronym: OPTYX
Pembro With Radiation With or Without Olaparib
NCT Number: NCT05568550
Phase:
Trial Summary: This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): Zin W Myint
Acronym:
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
NCT Number: NCT04995198
Patient Summary
Phase:
Trial Summary: PROMISE aims to create a comprehensive nationwide registry of prostate cancer patients with germline pathogenic variants by prospectively screening approximately 5,000 subjects with a confirmed prostate cancer diagnosis, either through tissue biopsy, PSA greater than 100 ng/dL and/or radiographic evidence of disease and receiving systemic therapy for prostate cancer. Patients at all stages of disease will be welcome to participate in the PROMISE Registry. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Prostate Cancer Clinical Trials Consortium
Acronym:
Pre-operative Education Modalities to Decrease Opioid Use
NCT Number: NCT04933084
Phase: NA
Trial Summary: This is a triple-armed, randomized, controlled, non-blinded trial to study the effect of preoperative patient education in conjunction with a limited opioid peri-operative analgesia program on post-op – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Benaroya Research Institute
Acronym:
Optimization of Prostate Biopsy – Micro-Ultrasound Versus MRI
NCT Number: NCT05220501
Phase: NA
Trial Summary: OPTIMUM is a study designed to compare the ability of ultra-high resolution transrectal micro-ultrasound (microUS) and multiparametric MRI (mpMRI)/US fusion to guide prostate biopsy. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sunnybrook Health Sciences Centre
Acronym: OPTIMUM
Clinical Trial of Approaches to Prostate Cancer Surgery
NCT Number: NCT05155501
Phase: NA
Trial Summary: This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatect – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym: PARTIAL
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
NCT Number: NCT05710380
Phase: NA
Trial Summary: Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Chicago
Acronym:
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT Number: NCT05864144
Phase: PHASE1|PHASE2
Trial Summary: Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cem – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sensei Biotherapeutics, Inc.
Acronym:
Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications
NCT Number: NCT04081636
Phase: NA
Trial Summary: This study evaluates the difference between 2 prostate biopsy methods, transrectal (through the rectal wall) and transperineal (through the skin) needle biopsy. Men who are in need of prostate biopsy – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Albany Medical College
Acronym: ProBE-PC
Physical Therapy for Men Undergoing Prostatectomy
NCT Number: NCT02558946
Phase: NA
Trial Summary: The purpose of this study is to determine if pelvic floor muscle training with a physical therapist before and after surgery will improve health-related quality of life following robot-assisted radica – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Indiana University
Acronym:
Transrectal Ultrasound Robot-Assisted Prostate Biopsy
NCT Number: NCT02871726
Phase: NA
Trial Summary: Prostate cancer (PCa) is the most common non-dermatologic malignancy in U.S. men. Transrectal ultrasound (TRUS)-guided prostate biopsy is a commonly used diagnostic procedure for men with an elevated – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Johns Hopkins University
Acronym:
A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality
NCT Number: NCT04565457
Phase: NA
Trial Summary: This is Pilot study that investigates the CBCT(Cone beam computed tomography) image quality improvement provided by the 2D antiscatter grid technology. The primary objective is to assess the improveme – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Colorado, Denver
Acronym:
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
NCT Number: NCT04573231
Phase: PHASE2
Trial Summary: The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive me – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Wisconsin, Madison
Acronym:
MR/TRUS Fusion Guided Prostate Biopsy – An Improved Way to Detect and Quantify Prostate Cancer
NCT Number: NCT04599218
Phase: NA
Trial Summary: This research study is designed to determine if targeted Magnetic Resonance Imaging (MRI) Ultrasound (US) fusion biopsy is better than the standard of care ultrasound guided biopsy alone in diagnosing – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Ardeshir Rastinehad
Acronym:
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
NCT Number: NCT05515978
Phase: Early Phase 1
Trial Summary: Metformin is used widely in the treatment of type 2 diabetes. It has off-label indications for use in the prevention of diabetes and in hyperinsulinar obesity. In medical practices, the implementation – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Colorado, Denver
Acronym:
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
NCT Number: NCT05519878
Phase: Not Applicable
Trial Summary: This clinical trial evaluates light therapy and occupational therapy in improving cancer related fatigue (CRF) patients with genitourinary cancers. Light therapy is a non-pharmacological and evidence- – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI)
Acronym:
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT Number: NCT05787587
Phase: Phase 1
Trial Summary: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): IDEAYA Biosciences
Acronym:
Predicting Location and Extent of Prostate Cancer Using Micro-Ultrasound Imaging
NCT Number: NCT04981223
Phase: Not Applicable
Trial Summary: The goal of this study is to use a clinical micro-ultrasound to systematically image the prostate before biopsy or surgery. The images from the ultrasound system will be saved and compared to other im – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Stanford University
Acronym:
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
NCT Number: NCT05679388
Phase: Phase 1
Trial Summary: Researchers leading this study hope to learn about the safety of combining the study drug relugolix with another study drug called itraconazole or ritonavir in prostate cancer. Thi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Chicago
Acronym:
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
NCT Number: NCT05722288
Phase: PHASE2
Trial Summary: This phase II trial studies how well time-restricted eating works in reducing side effects of radiation or chemoradiation side effects when compared to nutritional counseling among – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): City of Hope Medical Center
Acronym:
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
NCT Number: NCT05605522
Phase: Phase 1
Trial Summary: This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fusion Pharmaceuticals Inc.
Acronym:
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
NCT Number: NCT05629494
Phase: Phase 4
Trial Summary: Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and ele – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Albany Medical College
Acronym: ADAPT-PSA
MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT Number: NCT05608694
Phase: Not Applicable
Trial Summary: The purpose of this study is to determine whether or not Magnetic Resonance Images (MRI) will identify high-grade cancers earlier and more frequently in men at high risk of develop – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Chicago
Acronym:
T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer
NCT Number: NCT05586360
Phase: Phase 2
Trial Summary: This study will evaluate whether simvastatin reduces intraprostatic immunosuppressive microenvironment through YAP-mediated T-reg dysfunction, and increases intraprostatic anti-tum – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Medical University of South Carolina
Acronym:
Wrist Cooling for Hot Flashes Clinical Trial
NCT Number: NCT05595213
Phase: NA
Trial Summary: This pilot randomized double blind controlled crossover study aims to determine the impact of two wrist cooling devices on symptom control of hot flashes in adult men with prostate – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Boston University
Acronym:
Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy
NCT Number: NCT05597878
Phase: Phase 2|Phase 3
Trial Summary: The objective of this study is to conduct a randomized clinical trial to evaluate an opioid versus an opioid-free pathway of perioperative use of ketamine, ketorolac, and IV acetam – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Wake Forest University Health Sciences
Acronym:
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
NCT Number: NCT05477823
Phase: Early Phase 1
Trial Summary: The purpose of this study is to evaluate the imaging and gene expression biomarkers in prostate cancer. Participants have high-risk prostate cancer and have indicated they will und – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Wisconsin, Madison
Acronym:
Improving Germline Testing in At-Risk Patients With Prostate Cancer
NCT Number: NCT05470036
Phase: Not Applicable
Trial Summary: A quality improvement initiative to improve rates of germline testing among men with prostate cancer through the use of an in-clinic educational sessi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of California, San Diego
Acronym: IMPRINT
Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
NCT Number: NCT05384535
Phase: Not Applicable
Trial Summary: To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protoc – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Northwell Health
Acronym:
T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
NCT Number: NCT05361798
Phase: Phase 2
Trial Summary: Prostate cancer is often treated with radiation and ADT (ADT is androgen deprivation therapy). Up to 30% of these cancers recur within 5 years of treatment. Researchers want to see – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Acronym:
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
NCT Number: NCT05351424
Phase: NA
Trial Summary: The study aims to develop educational media interventions to prepare Latinx Spanish-speaking radiation oncology patients for a course of breast or prostate cancer radiation therapy – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Columbia University
Acronym: ADELANTE
Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care
NCT Number: NCT05366842
Phase: Phase 2
Trial Summary: Surgical implantation of Lyopreserved Placental Tissue (LPT) is FDA approved and has been used extensively in wound care. The use is expanding and more recently, LPT has been used – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Johns Hopkins University
Acronym:
AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
NCT Number: NCT05375539
Phase: PHASE1
Trial Summary: This study is to obtain acute dose safety and pharmacokinetics/pharmacodynamics (PK/PD) data in a dose-response trial in prostate cancer patients. – see link above for more informa – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Milton S. Hershey Medical Center
Acronym:
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
NCT Number: NCT05327465
Phase: NA
Trial Summary: The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk fact – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym:
Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study
NCT Number: NCT05327452
Phase: NA
Trial Summary: The purpose of this research is to determine whether a 16 week, home-based, aerobic and resistance exercise intervention will increase physical activity levels in Black and Hispani – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym:
An Imaging Agent (Perflutren Lipid Microspheres) With Ultrasound for Imaging of Prostate Cancer
NCT Number: NCT05336786
Phase: Phase 3
Trial Summary: This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Thomas Jefferson University
Acronym:
Social Risk Factors and Discrimination in Cancer Survivorship
NCT Number: NCT05301114
Phase: NA
Trial Summary: The objective of the proposed study is to scale social risk factor screening and referral for cancer survivors and to solidify information exchange between clinical and community s – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Medstar Health Research Institute
Acronym:
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
NCT Number: NCT05160597
Phase: Early Phase 1
Trial Summary: This early phase I trial studies how well an image-guided prostate biopsy using the imaging agent 68Ga-prostate-specific membrane antigen (PSMA)-11 with a positron emission tomogra – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Jonsson Comprehensive Cancer Center
Acronym:
Methods for Increasing Genetic Testing Uptake in Michigan
NCT Number: NCT05162846
Phase: NA
Trial Summary: The primary purpose of this study is to compare three interventions, two experimental and one standard of care (usual care), to see if the experimental interventions will increase – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Michigan Rogel Cancer Center
Acronym: MiGHT
Massage for Prostate Cancer-Related Fatigue, mPROSTATE Study
NCT Number: NCT05067777
Phase: Phase 2
Trial Summary: This phase II trial investigates the effect of massage in decreasing prostate cancer-related fatigue. Massage therapy has well known health benefits. This trial aims to find out if – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Utah|National Cancer Institute (NCI)
Acronym: mPROSTATE
COAST Therapy in Advanced Solid Tumors and Prostate Cancer
NCT Number: NCT05036226
Phase: Phase 1|Phase 2
Trial Summary: The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydro – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Medical University of South Carolina
Acronym: COAST
Post-prostatectomy Radiation Therapy–Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
NCT Number: NCT05038332
Phase: Phase 2
Trial Summary: The primary purpose of this study is to compare the quality of life (QOL) reported by prostate cancer patients 2 years after treatment with ultra-hypofractionated post-prostatectom – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Michigan Rogel Cancer Center
Acronym:
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
NCT Number: NCT05043012
Phase: Not Applicable
Trial Summary: Multiparametric MRI (mpMRI) of the prostate is an important tool for diagnosis of clinically significant prostate cancer (csPCa) in men with an elevated serum prostate specific ant – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): M.D. Anderson Cancer Center
Acronym:
Fluorescent Imaging of Nerves With Illuminare-1 During Surgery
NCT Number: NCT04983862
Phase: PHASE1
Trial Summary: This study will test the safety of using Illuminare-1 during standard surgery for prostate cancer. The study researchers will test increasing doses of Illuminare-1 to find the dose – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Memorial Sloan Kettering Cancer Center
Acronym:
Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer
NCT Number: NCT04981834
Phase: Not Applicable
Trial Summary: This phase III trial compares the effects of robot-assisted radical prostatectomy (RARP) with or without vesicopexy on urinary continence (a person’s ability to control their bladd – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Southern California|National Cancer Institute (NCI)
Acronym:
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
NCT Number: NCT04945642
Phase: Not Applicable
Trial Summary: This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma. Brachytherapy, als – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Jonsson Comprehensive Cancer Center
Acronym: HYDRA
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
NCT Number: NCT04947254
Phase: Phase 2
Trial Summary: This phase II trial studies the effect of androgen ablation therapy with or without niraparib after standard of care radiation therapy in treating patients with prostate cancer tha – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): M.D. Anderson Cancer Center
Acronym:
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
NCT Number: NCT04915508
Phase: Phase 2
Trial Summary: This phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has risi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Jonsson Comprehensive Cancer Center
Acronym: EXCALIBUR
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy
NCT Number: NCT04905069
Phase: Not Applicable
Trial Summary: To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat pr – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Boston Scientific Corporation
Acronym: SABRE
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
NCT Number: NCT04890613
Phase: Phase 1
Trial Summary: This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients w – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Senhwa Biosciences, Inc.
Acronym:
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
NCT Number: NCT04857502
Phase: Early Phase 1
Trial Summary: This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I&S in patients with prostate cancer who undergo pelvic lymph node dissection. Pr – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Jonsson Comprehensive Cancer Center
Acronym:
Improving Care After Inherited Cancer Testing
NCT Number: NCT04763915
Phase: NA
Trial Summary: The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genet – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Vanderbilt-Ingram Cancer Center
Acronym: IMPACT
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
NCT Number: NCT04725903
Phase: Not Applicable
Trial Summary: This phase II trial investigates whether proton radiation therapy directed to the prostate tumor, pelvic, and para-aortic lymph nodes, is an effective way to treat patients with hi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Emory University|National Cancer Institute (NCI)
Acronym:
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
NCT Number: NCT04698564
Phase: Phase 2
Trial Summary: This is a two-tiered pilot study in which there will be no randomization and no placebo treatment. This study will be to perform metabolic magnetic resonance imaging on men suspect – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Maryland, Baltimore
Acronym:
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
NCT Number: NCT04700332
Phase: Phase 2
Trial Summary: The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be sub – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Hoag Memorial Hospital Presbyterian
Acronym:
Brain and Pelvic Floor Muscle Activity of Patients Undergoing Robot-Assisted Radical Prostatectomy
NCT Number: NCT04646434
Phase: Not Applicable
Trial Summary: This trial investigates brain and pelvic floor muscle activity in patients undergoing robot-assisted radical prostatectomy. This trial may help identify the brain waves that are as – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Roswell Park Cancer Institute
Acronym:
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT Number: NCT04644068
Phase: Phase 1|Phase 2
Trial Summary: This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-can – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): AstraZeneca
Acronym: PETRA
Researching the Effect of Exercise on Cancer
NCT Number: NCT04589468
Phase: NA
Trial Summary: Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Memorial Sloan Kettering Cancer Center
Acronym:
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
NCT Number: NCT04530552
Phase: Phase 2
Trial Summary: This phase IIa trial investigates the biomarker (plasma levels of PSA) of low-dose apalutamide in patients with prostate cancer confined in the prostate gland before surgery. Testo – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT Number: NCT04550494
Phase: Phase 2
Trial Summary: This phase II trial studies if talazoparib works in patients with cancer that has spread to other places in the body (advanced) and has mutation(s) in deoxyribonucleic acid (DNA) d – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
NCT Number: NCT04486755
Phase: Phase 1
Trial Summary: A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, sim – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Maryland, Baltimore
Acronym:
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
NCT Number: NCT04465500
Phase: Phase 2
Trial Summary: This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Virginia
Acronym: Prostate005
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
NCT Number: NCT04349501
Phase: Phase 2
Trial Summary: Adult male patients with high-risk, localized prostate cancer and planning to undergo radiation therapy (RT) with androgen deprivation therapy (ADT) will undergo an advanced Magnet – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of California, San Diego
Acronym: ProsRSI
The Impact of Low Pressure Pneumo in RARP II
NCT Number: NCT04394676
Phase: Not Applicable
Trial Summary: The purpose of this study is to evaluate clinical significance of low pressure pneumoperitoneum during robotically assisted radical prostatectomy (RAR – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Metro Health, Michigan
Acronym:
AMNIOX CORD Study – Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
NCT Number: NCT04263025
Phase: PHASE2|PHASE3
Trial Summary: This study aims at evaluating if placement of CLARIX® CORD 1K during robotic prostatectomy decreases the time to achieve complete erectile and urinary function after the surgery. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Hackensack Meridian Health
Acronym:
Onco-primary Care Networking to Support TEAM-based Care
NCT Number: NCT04258813
Phase: NA
Trial Summary: The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Duke University
Acronym: ONE TEAM
Serial MRI Scans During Radiation Therapy
NCT Number: NCT04188535
Phase: Not Applicable
Trial Summary: This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (s – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym: RELAY
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
NCT Number: NCT03987386
Phase: Phase 3
Trial Summary: This phase III trial studies how well hypofractionated radiation therapy works compared to the conventional one in treating patients with prostate cancer. Radiation therapy uses hi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Acronym:
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
NCT Number: NCT03976843
Phase: Phase 2
Trial Summary: People with prostate cancer usually have their cancer imaged with a CT scan and bone scan. They then have their prostate gland removed. Researchers want to test a scan that might p – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Acronym:
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
NCT Number: NCT03880422
Phase: Not Applicable
Trial Summary: This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nu – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Roswell Park Cancer Institute
Acronym:
The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer
NCT Number: NCT03808077
Phase: Phase 2
Trial Summary: The purpose of this study is to determine if there is a difference in intra-abdominal pressure which surgeons use during surgery and post-surgery pain in men who undergo robotic pr – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Memorial Sloan Kettering Cancer Center
Acronym:
HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
NCT Number: NCT03802851
Phase: Not Applicable
Trial Summary: To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Kansas Medical Center
Acronym: HOLEP-RTPC
CyberKnife Dose Escalation Prostate Cancer Trial
NCT Number: NCT03822494
Phase: Not Applicable
Trial Summary: Stereotactic body radiation therapy (SBRT) has been employed in the treatment of prostate cancer. Multiple single institution experiences suggest high biochemical control rates wit – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Crozer-Keystone Health System
Acronym: CK-DESPOT
Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer
NCT Number: NCT03772834
Phase: Phase 2|Phase 3
Trial Summary: This phase II/III trial studies how well methylphenidate and exercise work in reducing cancer-related fatigue in patients with prostate cancer. Methylphenidate is a type of central – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Acronym:
Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer
NCT Number: NCT03697148
Phase: Not Applicable
Trial Summary: This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate canc – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group
Acronym:
Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy
NCT Number: NCT03585660
Phase: NA
Trial Summary: The purpose of the proposed research is to test and validate a Risk Map decision-support system (DSS) for prostate cancer Magnetic Resonance Imaging (MRI) interpretation and identi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Chicago
Acronym:
Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
NCT Number: NCT03496805
Phase: PHASE2
Trial Summary: It is estimated that one-third of the more than 7 million deaths from cancer worldwide are attributable to potentially modifiable risk factors, with 374,000 deaths preventable thro – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Wake Forest University Health Sciences
Acronym:
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
NCT Number: NCT03232164
Phase: Early Phase 1
Trial Summary: The overall goal of this research is to validate and develop a non-invasive imaging biomarker of prostate cancer detection, progression, and recurrence. Development of such a bioma – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Wisconsin, Madison
Acronym:
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
NCT Number: NCT02717156
Phase: Phase 2
Trial Summary: This is a multi-cohort single arm phase II/screening trial of the combination of a fusion protein that binds EphrinB2 and blocks interaction with cell surface EphB receptors (sEphB – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Southern California|National Cancer Institute (NCI)
Acronym:
Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy
NCT Number: NCT02307058
Phase: Not Applicable
Trial Summary: The purpose of this research study is to learn about: 1) improving control of prostate cancer using an extra high dose radiation treatment to the MRI defined high risk tumor areas, – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Miami
Acronym: BLaStM
Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer
NCT Number: NCT02334579
Phase: Not Applicable
Trial Summary: The purpose of this study is to find out the effects (good and bad) of highly focused radiation on you and your prostate cancer. The purpose of this evaluation is to see if this tr – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Swedish Medical Center
Acronym:
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
NCT Number: NCT02526368
Phase: EARLY PHASE1
Trial Summary: This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon C13 pyruvate works in finding prostate cancer that exhibits po – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of California, San Francisco
Acronym: pyruvate
Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer
NCT Number: NCT02016248
Phase: Not Applicable
Trial Summary: The purpose of this study is to determine the side effects and how effective CyberKnife stereotactic ablative body radiation (SABR) is in patients with prostate cancer. The CyberKn – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): MemorialCare Health System
Acronym:
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
NCT Number: NCT01985828
Phase: Not Applicable
Trial Summary: The primary objective of this study is to document the effectiveness of Cyberknife stereotactic body radiotherapy (SBRT) in the treatment of intermediate and high-risk localized pr – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Advocate Health Care
Acronym:
MRI for Assessing Prostate Cancer Response
NCT Number: NCT01607008
Phase: Not Applicable
Trial Summary: Prostate cancer is one of most common cancers in America, affecting 1 in 6 men. External beam radiation therapy is one of the common methods to treat prostate cancer. Although radi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acronym: NA_00067284
Trial of Modifications to Radical Prostatectomy
NCT Number: NCT01407263
Phase: Phase 3
Trial Summary: This trial will evaluate whether the following aspect of surgical technique influence outcome: Lymph node dissection. In some patients, scans taken before surgery show that a lymph – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Memorial Sloan Kettering Cancer Center
Acronym:
Find Your Trial
Low Risk
Intermediate Risk
High Risk
Cancer Recurrence
Non-Metastatic Castration Resistant
Metastatic Castration Sensitive
Metastatic Castration Resistant
Promise Registry - All Risk Levels
PROMISE is a nationwide registry of prostate cancer patients with inherited mutations by screening approximately 5,000 participants with a prostate cancer diagnosis. The PROMISE team is studying how these mutations affect patient outcomes.
This information is for educational purposes only and not intended as medical advice.
Patients should consult their medical doctor for advice and recommendations about specific clinical trials.